Sarepta CEO on what's next after expanded muscular dystrophy drug approval

Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.

Jun 22, 2024 - 16:00

0 4

Sarepta CEO on what's next after expanded muscular dystrophy drug approval

Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.

Tags:

Previous Article

Tesla internal data shows company has slashed at least 14% of workforce this year

Consumer spending, inflation, and housing are 3 things to watch in the market ne...

admin

admin

This website uses cookies to enhance your browsing experience. By continuing to use this site, you consent to the use of cookies. Please review our Privacy Policy for more information on how we handle your data.